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Objective: Myocyte death occurs by necrosis and caspase-mediated apoptosis in the
setting of myocardial infarction. In vitro studies suggest that caspase activation
within myocytes causes contractile protein degradation without inducing cell death.
Thus, caspase activation may evoke left ventricular remodeling through 2 indepen-
dent processes post-myocardial infarction. However, the effects of caspase activa-
tion on left ventricular geometry post-myocardial infarction remain unclear. This
project applied broad-spectrum caspase inhibition to a chronic porcine model of
myocardial infarction.
Methods: Coronary snares and sonomicrometry crystals in remote and area-at-risk
regions were placed in pigs (n  22, 34 kg). Geometric measurements at end
diastole and end systole, including left ventricular area by echocardiography and
interregional distance by sonomicrometry, were obtained at baseline. Coronary
occlusion was instituted for 60 minutes, followed by reperfusion and repeated
geometric measurements at 7 days, including left ventriculography. At reperfusion,
pigs were randomized to saline (n  12) or caspase inhibition (n  10, IDN6734,
2 mg/kg intravenously, then 2 mg · kg · h for 24 hours) at a dose that achieved
desired plasma concentrations (790  142 ng/mL) as predicted by prior pharma-
cokinetic studies.
Results: Infarct size and 24-hour troponin-I values were not significantly different
between the saline and caspase inhibition groups (51% 8% vs 42% 6% and 189
 20 ng/mL vs 152  26 ng/mL, respectively, P  .10). At 7 days, end-diastole
volume was increased in both groups compared with reference control values (47
1 mL, P .05), but it was decreased with caspase inhibition (72 4 mL) compared
with saline (84  4 mL, P  .05). Similarly, end-diastole and end-systole areas
increased by 32%  3% and 81%  16% in the saline group but were attenuated
with caspase inhibition (19%  3% and 31%  10%, respectively, P  .05).
End-diastole interregional distance increased by 30%  7% in the saline group but
was attenuated with caspase inhibition (12%  5%, P  .05).
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Conclusion: Despite equivalent degrees of myocardial injury, caspase inhibition
reduced post-myocardial infarction left ventricular remodeling as evidenced by
multiple, independent assessments of left ventricular dilation. Thus, caspase acti-
vation alters left ventricular geometry in the absence of significant effects on
myocardial injury.
Left ventricular (LV) remodeling is a struc-tural consequence of prolonged myocardialischemia or myocardial infarction (MI).1The extent of LV remodeling is commonlyquantified by assessing changes in the ge-ometry of the LV chamber (volume and di-
mension) that ensue after the onset of alterations in both the
cellular and extracellular myocardial compartments. A cel-
lular event that forms the underpinning of LV remodeling
processes is ischemia-induced alterations in myocyte struc-
ture and viability.2 Although MI has been clearly demon-
strated to occur as a direct result of ischemia-induced myo-
cyte necrosis, “programmed cell death,” or apoptosis, has
recently been described as an important contributing entity
in the evolution of MI.3,4 Moreover, recent in vitro and in
vivo studies have demonstrated that modulation of the ap-
optotic cascade may improve myocardial viability5-8 and
function5,8 in the context of short durations of ischemia-
reperfusion (I/R). However, whether and to what degree the
results of these past basic studies can be translated to large
animal models of MI that may more closely resemble the
clinical setting of MI remain unknown.
The caspases are an endogenous family of intracellular
cysteine proteases that participate in critical steps of the
apoptotic cascade in numerous pathologic processes includ-
ing cerebrovascular accidents, neurodegenerative disorders,
and acquired immunodeficiency syndrome.9 More recently,
caspases have been described to modulate myocyte apopto-
sis, particularly in the setting of myocardial ischemia.10,11
Specifically, interruption of caspase activity using pharma-
cologic inhibition has been demonstrated to attenuate myo-
cardial injury in vitro12 and in vivo8 after a limited period of
regional ischemia. However, whether and to what degree
caspase inhibition (CASPI) may affect LV geometry in the
post-MI setting remain unknown. Accordingly, the present
study examined the effects of broad-spectrum pharmaco-
logic CASPI on regional and global LV geometry in a
porcine model of MI.
Methods
Study Rationale and Overview
The present study used a chronic porcine model in which the
effects of broad-spectrum pharmacologic CASPI on indices of LV
remodeling were assessed after the induction of MI. Pigs were
used as an animal model because they exhibit coronary artery
anatomy and cardiac physiology similar to that of humans.13 A
broad-spectrum caspase inhibitor (IDN6734, Idun Pharmaceuti-
cals, San Diego, Calif) was instituted immediately before myocar-
dial reperfusion and was continued for a period of 24 hours
post-MI. IDN6734 was administered at the time of reperfusion to
simulate the common clinical scenario of MI in which pharmaco-
logic intervention is administered, and coronary reperfusion is
frequently reestablished only after a significant duration of isch-
emia. A broad-spectrum CASPI with a similar structure has been
characterized and demonstrated to prevent caspase-induced car-
diomyopathy.14 All animals were treated and cared for in accor-
dance with the National Institute of Health “Guide for the Care and
Use of Laboratory Animals” (National Research Council, Wash-
ington, 1996).
Experimental Design
Instrumentation. Yorkshire pigs (n  22, 34 kg, Hambone
Farms, Orangeburg, SC) were anesthetized with isoflurane (3%/1.5
L/min) and nitrous oxide (0.5 L/min). Through a left anterolateral
thoracotomy, catheters (7-Fr) connected to subcutaneous access
ports were sutured into the descending thoracic aorta and pulmo-
nary artery. A disengaged coronary snare device was placed
around the circumflex coronary artery immediately distal to the
first obtuse marginal branch (Figure 1). Two pairs of piezoelectric
crystals (2 mm, Sonometrics, Ontario, Canada) were advanced into
the LV chamber and secured adjacent to the endocardial surface.
The first crystal pair was placed between the first and second
diagonal branches of the left anterior descending coronary artery,
and the second pair was placed between the third and fourth obtuse
marginal branches of the circumflex coronary artery. The distal
ends of the sonomicrometry crystal cables coalesced into a single
connector hub that was tunneled out of the chest and buried within
a subcutaneous pocket along with the distal end of the coronary
snare device. The incisions were closed in layers, and the pigs
were allowed to recover.
Randomization. After 5 days of recovery, the pigs were ran-
domized (Figure 1) in a blinded fashion to saline (n  12) or
CASPI (n  10, IDN6734, 2 mg/kg intravenously [IV], followed
by 2 mg · kg · h for 24 hours). The dosing regimen for IDN6734
achieved desired plasma concentrations (790  142 ng/mL) as
predicted by prior pharmacokinetic studies. A total of 11 normal,
age-matched, noninstrumented pigs were included for comparison.
Treatment codes were not broken until the entire study was
completed.
Baseline measurements. Two-dimensional and M-mode LV
echocardiographic images (ATL Ultramark VI, 2.25 MHz trans-
ducer, Bothell, Wash) were obtained from a right parasternal
approach. The short and long-axis 2-dimensional targeted images
Yarbrough et al Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 6 1893
CS
P
were gated to continuous electrocardiograms to define end systole
and end diastole, and short- and long-axis LV areas were deter-
mined. The subcutaneous aortic and pulmonary artery ports were
accessed to collect plasma, transduce arterial pressure, and deliver
appropriate antiarrhythmics and heparin (150 U/kg, Pharmacia and
Upjohn, Kalamazoo, Mich). The disengaged snare devices and
sonomicrometry crystal hubs were exteriorized from their subcu-
taneous pockets in a sterile fashion. The sonomicrometry crystals
were used to assess the distance between the remote and area-at-
risk regions at end systole and end diastole.
MI induction. Coronary snare engagement resulted in proxi-
mal occlusion of the circumflex coronary artery and produced
myocardial injury that was immediately confirmed by standard
limb-lead electrocardiographic and hemodynamic changes. Epi-
sodes of ventricular tachycardia and fibrillation were terminated
with lidocaine (50 mg, Elkins-Sinn, Cherry Hill, NJ) and external
defibrillation, respectively. After 60 minutes of coronary occlu-
sion, the snares were disengaged and the pigs were reperfused.
Pigs randomized to CASPI received a bolus of IDN6734 (2 mg/kg,
IV) immediately before reperfusion followed by a continuous
infusion (2 mg/kg/h, IV) for a period of 24 hours. IDN6734 was
administered through the pulmonary artery catheter. The disen-
gaged snares and crystals hubs were returned to their subcutaneous
pockets, and the wounds were closed.
Terminal measurements. At 7 days post-MI, echocardio-
graphic and sonomicrometry crystal measurements were repeated.
Subsequently, a full anesthetic induction and instrumentation pro-
cedure was performed as previously described to obtain systemic
hemodynamic measurements, LV and pulmonary artery pressures,
and indices of global function.15 LV volumes were computed from
ventriculograms as described previously.16 The LV was explanted,
and mid-ventricular, short-axis, and circumferential sections were
obtained for tetrazolium chloride staining and infarct size estima-
tion.17 Infarct size was computed as a percentage of the myocardial
area-at-risk. Systemic hemodynamics and indices of global func-
tion were similarly determined in the control pigs.
Data analysis. Changes in hemodynamic, functional, and geo-
metric values between the saline and CASPI groups were analyzed
with a 2-way analysis of variance followed by mean separation
with pair-wise Bonferroni corrections. Values are presented as the
mean and SEM.
Results
External defibrillation for ventricular fibrillation was re-
quired in 18% of the pigs during the 60-minute ischemic
interval with no difference between MI groups (Pearson
corrected 2 analysis, P  .97). There were no episodes of
ventricular fibrillation during the reperfusion interval. At 24
hours post-MI, plasma cardiac troponin-I values were not
significantly different between the saline and CASPI groups
(189  20 ng/mL vs 152  26 ng/mL, respectively, P 
.21) (Figure 2). At 7 days after coronary occlusion and
release, myocardial infarct size was not statistically differ-
ent between the saline and CASPI groups (51%  8% vs
42%  6%, respectively, P  .40) (Figure 2).
Steady-State Hemodynamics
Steady-state hemodynamics obtained at 7 days post-MI are
presented in Table 1. LV end-diastolic pressure was in-
creased in both MI groups compared with control values.
There were no significant differences in heart rate, cardiac
output, or LV-developed pressure between the control or MI
groups. However, compared with control values, mean aor-
tic and LV peak pressures were decreased in the CASPI
group.
Interregional Geometry and Contractile Function
The distances, or chord lengths, between sonomicrometry
crystals positioned within the remote and area-at-risk re-
gions were determined at end diastole and end systole in
both MI groups (Figure 3). The end-diastolic and end-
systolic chord lengths were increased at 7 days post-MI in
both MI groups compared with baseline values. However,
end-diastolic and end-systolic chord lengths were reduced
in the CASPI group compared with the saline group values.
LV interregional shortening was determined at 7 days
post-MI between the remote and area-at-risk regions in both
groups as well (Figure 3). Interregional shortening was
reduced in the saline group compared with baseline values.
However, administration of CASPI preserved LV interre-
gional shortening compared with saline group values.
Global Left Ventricular Geometry
Global LV geometry was assessed using long-axis echocar-
diography at baseline and at 7 days post-MI (Figure 4). LV
end-diastolic and end-systolic areas were increased at 7
days post-MI in both groups compared with baseline values,
but this was significantly attenuated with the institution of
CASPI at the time or myocardial reperfusion compared with
saline values (Figure 4). Left ventriculograms performed
during terminal investigations provided additional indepen-
dent assessments of global LV geometry and function (Ta-
ble 1). Compared with control values, LV end-diastolic and
end-systolic volumes were increased, and LV ejection frac-
tion was decreased, in the saline group at 7 days post-MI.
Administration of CASPI significantly attenuated LV dila-
tion after MI and seemed to improve ejection fraction com-
pared with saline values, although statistical significance
was not reached.
Discussion
MI disrupts the dynamic architecture of the LV wall and can
result in chamber dilation. This process, termed “LV re-
modeling,” has been demonstrated to be an independent
determinant of morbidity and mortality after MI.18 Notably,
pharmacologic strategies designed to interrupt specific cel-
lular and extracellular pathways causative to post-MI LV
remodeling, such as excessive neurohormonal stimulation,
have had favorable effects on morbidity and mortality.19
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Recent investigations suggest that modulation of intracellu-
lar caspases, the primary effectors of cell death by apopto-
sis, may hold significant therapeutic potential as a treatment
modality in the setting of myocardial I/R.5-8,12,20 Specifi-
cally, ischemia-induced myocardial injury was attenuated in
vitro by interrupting intracellular caspase activity and by
protecting against activated caspases through the use of
pharmacologic12 and genetic interventions,5-7 respectively.
Figure 1. Top, The experimental design included a 5-day recovery period after basic instrumentation. After 60
minutes of regional myocardial ischemia, pigs were randomized to saline or CASPI groups. Terminal measure-
ments obtained at 7 days post-MI included left ventriculograms. Bottom, left, A schematic of the heart after basic
instrumentation. A disengaged snare device was placed around the proximal circumflex coronary artery. Sonomi-
crometry crystals were positioned within the anterior (remote region) and posterolateral (area-at-risk, shaded) LV
surfaces. Access ports were sutured into the descending thoracic aorta and pulmonary artery trunk (not shown).
Bottom, right, A depiction of the LV as observed from a view perpendicular to the long-axis. Sonomicrometry
crystal heads are apparent along the endocardial surface of the LV. CASPI, Caspase inhibition; LAD, left anterior
descending.
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However, most of these past studies used ischemic intervals
of short duration and examined myocardial injury, as as-
sessed by infarct size as a primary end point. Thus, the
effects of modulating caspase activity on LV remodeling in
a large animal model of MI that may resemble a common
clinical scenario remain to be defined. Accordingly, the
primary objective of the present study was to test the central
hypothesis that broad-spectrum CASPI would favorably
alter regional and global LV remodeling in a chronic por-
cine model of MI. The unique findings of the present study
were 2-fold. First, when instituted at the time of reperfusion,
broad-spectrum CASPI attenuated regional and global LV
remodeling during the acute post-MI period. Second, the
observed reductions in LV dilation post-MI were achieved
in the absence of significant effects on absolute myocyte
troponin-I release and MI size.
Caspases and the Apoptotic Cascade
Prolonged periods of myocardial ischemia evoke myocyte
death through 2 distinct and time-dependent processes,
namely, necrosis and apoptosis.10,21 In past experimental
settings, most myocytes that succumbed to acute and per-
Figure 2. Myocardial injury was assessed by determining LV infarct size at 7 days post-MI (left) and plasma
troponin-I values 24 hours after MI creation (right). There were no statistically significant differences between the
MI groups with respect to these parameters. MI, Myocardial infarction.
Figure 3. At baseline and at 7 days post-MI, end-diastolic and end-systolic chord lengths were determined
between the remote and area-at-risk regions (left) yielding distances that approximated the diameter of the LV and
facilitated assessments of interregional shortening (right). LV end-diastolic and end-systolic chord lengths were
increased, and interregional shortening was reduced in the saline group at 7 days post-MI. CASPI significantly
attenuated these geometric and functional changes. (#P < .05 vs baseline and *P < .05 vs saline.)
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manent myocardial ischemia were believed to have died by
necrosis.22 On the contrary, recent studies have demon-
strated that apoptosis, an energy-dependent process, repre-
sents a particularly important myocyte death mechanism in
the setting of I/R.5-8,12,20 Through the use of genetic ma-
nipulation and pharmacologic CASPI, these past investiga-
tions provided proof of concept that caspases are intricately
involved in the apoptotic process. However, as evidenced
by a recent in vitro investigation,23 activation of intracellu-
lar caspases within isolated myocytes was demonstrated to
evoke deteriorations in contractile function through the deg-
radation of cytosolic contractile elements without a cellular
commitment to apoptosis. Taken together, the results of
these basic investigations indicate that intracellular caspases
likely play multiple roles within myocytes. The present
study builds on the results of these past investigations by
using broad-spectrum CASPI in a chronic large animal
model of MI. This unique model not only facilitated assess-
ment of myocardial injury during the acute and subacute
peri-infarction periods but also allowed subsequent changes
in regional and global LV geometry post-MI to be assessed.
Caspase Inhibition and Myocardial Injury
Numerous past studies have demonstrated that modulation
of caspase activity attenuated myocardial injury in the set-
ting of I/R.5-8,12,20 For instance, Gustafsson and investiga-
tors7 used transgenetic rodent models to report that manip-
ulation of caspase activity resulted in significant reductions
in infarct size and creatine kinase efflux. However, many of
these preclinical investigations used limited durations of
myocardial ischemia in conjunction with isolated whole-
heart preparations.5-7,12 The present study is unique in that
a chronic large animal model of MI was used that more
closely recapitulated the clinical context. Because the tar-
geted myocardial regions used in the present study were
devoid of significant collateral vessels,13 an extensive
amount of tissue loss was caused by the prolonged ischemic
interval as evidenced by the marked elevations in plasma
cardiac troponin-I values observed in both MI groups at 24
hours post-MI. Moreover, the substantial plasma release of
troponin-I at 24 hours may indicate that necrosis repre-
sented the dominant pattern of cell death during the acute
peri-infarction period. However, whether and to what de-
gree myocyte apoptosis contributed to the increase in
plasma troponin-I remain unknown. Institution of broad-
spectrum CASPI immediately before reperfusion, although
unable to salvage myocardial tissue lost by necrosis during
the ischemic interval, may have attenuated additional myo-
cyte death within the infarct border zones by apoptotic
cascades. Preservation of myocyte viability within the rel-
atively small mass of the infarct border zone may provide an
explanation as to why CASPI seemed to reduce infarct size
and troponin-I release without reaching statistical signifi-
TABLE 1. Systemic hemodynamics, left ventricular geom-
etry, and myocardial injury 7 days post-myocardial infarc-
tion: Effects of caspase inhibition
Control Saline CASPI
Systemic hemodynamics
Heart rate (beats/min) 93 4 95 3 96 5
Cardiac output (L/min) 3.5 0.2 3.5 0.2 3.3 0.3
Mean aortic pressure
(mm Hg)
79 3 73 5 67 4*
LV peak systolic pressure
(mm Hg)
101 3 91 6 86 5*
LV end-diastolic pressure
(mm Hg)
5 1 11 2* 14 1*
Mean pulmonary artery
pressure (mm Hg)
13 1 11 2 14 2
LV volumes
End-diastolic volume (mL) 47 1 84 4* 72 4*†
End-systolic volume (mL) 12 2 47 4* 38 4*
Ejection fraction (%) 76 4 45 4* 49 4*
Myocardial injury
Infarct size (%) — 51 8 42 6
24-h cardiac troponin-I
(ng/mL)
— 189 20 152 26
Sample size (n) 11 12 10
CASPI: IDN6734 (2 mg/kg bolus followed by 2 mg · kg · h infusion for 24 h),
a broad-spectrum caspase inhibitor, was instituted after 60 min of regional
ischemia at the time of myocardial reperfusion.
MI, Myocardial infarction; CASPI, caspase inhibition; LV, left ventricular.
*P  .05 vs control.
†P  .05 vs saline.
Figure 4. LV end-diastolic and end-systolic areas presented as
changes from baseline. At 7 days post-MI, LV areas were in-
creased in both MI groups compared with baseline values. How-
ever, institution of CASPI conferred significant reductions in LV
dilation compared with saline values. (#P < .05 vs baseline and
*P < .05 vs saline.)
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cance. Histologic examination of border-zone tissue may be
warranted to address this issue more closely. Nevertheless,
the results of the present study clearly indicate that broad-
spectrum CASPI attenuated LV remodeling post-MI in the
absence of significant effects on myocyte troponin-I release
and MI size.
Left Ventricular Remodeling After Myocardial
Infarction
The potential implications of apoptosis in the pathogenesis
of LV remodeling post-MI have been studied.24,25 For ex-
ample, Palojoki and investigators25 used terminal de-
oxynucleotide transferase-mediated dUTP nick-end labeling
(TUNEL) methodology in a chronic rodent model of MI to
demonstrate that apoptosis occurred within both remote and
border-zone regions. In the present study, the effects of
CASPI on regional and global LV geometry were evaluated
at 7 days post-MI. Because myocardial apoptosis peaks
approximately 12 hours post-MI,26 qualitative and quanti-
tative assessments of myocardial apoptosis were not used.
Therefore, whether and to what degree CASPI attenuated
apoptosis within the infarct border zones remain to be
determined. Use of TUNEL, fluorescent-annexin V stain-
ing, or caspase-3 assays would likely yield important infor-
mation with respect to this matter. Nevertheless, in the
present study, broad-spectrum CASPI was associated with
significant reductions in multiple, independent assessments
of LV remodeling post-MI, namely, LV area (echocardiog-
raphy), volume (ventriculography), and interregional chord
length (sonomicrometry). It is probable that broad-spectrum
pharmacologic inhibition attenuated the effects of caspase
activation within the border zone evoked by the generation
of reactive oxygen species on reperfusion and increased LV
wall stress post-MI, factors known to induce apoptosis in
vitro.27,28 Institution of CASPI at the time of reperfusion,
and throughout the following 24 hours, likely rendered the
caspases incapable of executing not only the apoptotic cas-
cade but also the cleavage of other intracellular substrates.
CASPI may have attenuated degradation of contractile pro-
teins located within viable myocytes contained in the infarct
border zone, thus providing an explanation for the improved
interregional function and trend toward increased ejection
fraction associated with the CASPI group. Subsequent at-
tempts to quantify the degree of myocardial contractile
protein degradation that occurred within each MI group may
therefore prove useful.
Study Limitations and Clinical Implications
The present study used broad-spectrum CASPI in a chronic
large animal model to assess changes in LV geometry
post-MI. Therefore, whether and to what degree CASPI
attenuated apoptosis within the infarct border zones remain
to be determined. Moreover, whether and to what degree
CASPI modulates LV geometry in the setting of permanent
coronary artery occlusion remain to be addressed. Never-
theless, the results of the present study indicate that caspases
may play multiple roles in the structural dynamics of the
myocardium post-MI. Broad-spectrum CASPI instituted at
the time of reperfusion attenuated regional and global LV
remodeling post-MI. Thus, strategies that modulate caspase
activation may hold significant therapeutic potential in the
setting of MI.
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Discussion
Dr Y. Joseph Woo (Philadelphia, Pa). Could you perhaps
elaborate a little more about exactly what aspect of your apoptotic
cascade that this agent blocks?
Second, did you measure your regional changes in contractility
from within the infarct to outside, effectively across the border
zone where most of this antiapoptotic effect would have its great-
est benefit?
Last, your laboratory probably has the most expertise in the
world regarding extracellular matrix modification, and I was won-
dering if you could comment a little bit more on potential rela-
tionships there.
Dr Yarbrough. With regard to your first question, we use a
broad-spectrum CASPI, and essentially it inhibited caspases 3, 6,
8, and 9, the major players in the apoptotic cascade. This was
determined essentially by in vitro investigations in which you
could take pure caspases, substrates for those caspases, and then
add an inhibitor and determine the IC50 and essentially try to
achieve that same compound concentration in vivo, which is what
we accomplished with this study.
The crystals were placed such that the border zone was in-
cluded. So the 2 crystals in the remote region were placed in the
left anterior descending region, and then the 2 crystals in the
area-at-risk region were placed on the posterior wall. So we did
include the border zone with respect to that interregional assess-
ment. It essentially approximated a diameter of the left ventricle,
kind of giving us a pseudo-global assessment of function.
With regard to your final question, the results of this study
essentially mirror what we have seen with broad-spectrum matrix
metalloproteinase inhibition in the MI model; that is, we see
beneficial attenuations in LV remodeling with not much of a
functional effect, at least within 1 or 2 weeks of the onset of drug
administration. In addition to that, we know that matrix metallo-
proteinases are activated, not only more abundant, but more acti-
vated in the myocardial interstitium within minutes of ischemia. So
taken together, we believe that somehow or another administration
of this agent is affecting matrix metalloproteinase activity and that
this is translating into beneficial attenuations in LV remodeling.
Dr Syed M. Quadri (Toronto, Ontario, Canada). I am won-
dering if you measured caspase activity in the tissue, in the
myocardium specifically, to verify that this was the pathway in-
volved?
Dr Yarbrough. We are in the process of doing that now. A lot
of the studies that we have looked at previously used ischemic
intervals of shorter duration, and they harvested tissue within hours
of the I/R injury. This study was a chronic study. We went 7 days.
So short of actually performing an endocardial biopsy during the
course of the study, we really only had tissue available at 7 days
post-MI.
We are in the process of performing the caspase 3 activity assay
in the remote region to try to assess whether or not there was any
difference between groups. I suspect that these data are going to
show very small differences. I think the bigger picture will be to
look at matrix metalloproteinase abundances and activities in those
regions at the same time point, and I think we will see a difference
with respect to that parameter.
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